Eli Lilly to acquire Ajax Therapeutics for $2.3B to bolster hematology pipeline
Eli Lilly (NYSE:LLY) has reached a definitive agreement to acquire Ajax Therapeutics, a biotechnology firm specializing in next-generation therapies for myeloproliferative neoplasms (MPNs).










